Advanced treatments, known as immunotherapies that activate T cells—our body’s immune cells—to eliminate cancer cells, have shown limited efficacy as standalone therapies for glioblastoma, the most lethal form of brain tumor. This is due to their minimal response to glioblastoma and high resistance to treatment.
This article was originally published on MedicalXpress.com